AI in Drug Development

Patent Updates | ADC Patents for the Week of August 7, 2025

by
Patent Updates | ADC Patents for the Week of August 7, 2025

August 7, 2025 Baiaoshaitu WO2025161939 FOLR1/MUC1 ADC On August 7, Baiaoshaitu disclosed an ADC patent targeting FOLR1 and FOLR1/MUC1. According to the data disclosed in the patent examples, the preferred structure for the FOLR1-targeted ADC is 1A3-CPT2, while the preferred structure for the FOLR1/MUC1 dual-targeted ADC is 10G1-1A3-CPT2; where 1A3 targets FOLR1 and 10G1 targets … Read more

Antibody-Drug Conjugates (ADCs): A Comprehensive Analysis from Basics to Frontiers

by
Antibody-Drug Conjugates (ADCs): A Comprehensive Analysis from Basics to Frontiers

Antibody-Drug Conjugates (ADCs) are precision anti-cancer drugs that combine the targeting ability of antibodies with potent cytotoxic agents, achieving precise strikes against tumor cells through a “biological missile” design. As of July 2025, a total of 19 ADC drugs have been approved globally, widely used in the treatment of various cancers such as breast cancer … Read more